The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments

International Journal of Antimicrobial Agents

Volumn 46, Issue 5, 2015, Pages 560-567

  Albur, Mahableshwar S ^a   Noel, Alan ^a   Bowker, Karen ^a   MacGowan, Alasdair ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Colistin; Combination; Fosfomycin; NDM; PK PD model; Time kill curve

Indexed keywords

COLISTIN; FOSFOMYCIN; METALLO BETA LACTAMASE; NEW DELHI METALLO BETA LACTAMASE 1; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE NDM-1;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE BACTERIUM; GROWTH REGULATION; IN VITRO STUDY; INOCULATION; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; DRUG EFFECTS; ENZYMOLOGY; MICROBIAL VIABILITY; SECRETION (PROCESS); THEORETICAL MODEL; TIME FACTOR;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COLISTIN; DRUG SYNERGISM; ENTEROBACTERIACEAE; FOSFOMYCIN; MICROBIAL VIABILITY; MODELS, THEORETICAL; TIME FACTORS;

EID: 84947019736     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.07.019     Document Type: Article

References (26)

1. World Health Organization Policy package to combat antimicrobial resistance 2011 WHO http://www.who.int/world-health-day/2011/presskit/WHDIntrototobriefs.pdf [accessed 17.08.15]
2. Centers for Disease Control and Prevention (CDC) Vital signs: carbapenem-resistant Enterobacteriaceae MMWR Morb Mortal Wkly Rep 62 2013 165 170
3. U. Theuretzbacher Accelerating resistance, inadequate antibacterial drug pipelines and international responses Int J Antimicrob Agents 39 2012 295 299
4. H.W. Boucher Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication Clin Infect Dis 50 2010 S4 S9
5. R.L. Nation, and J. Li Colistin in the 21st century Curr Opin Infect Dis 22 2009 535 543
6. M.E. Falagas, A.C. Kastoris, A.M. Kapaskelis, and D.E. Karageorgopoulos Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review Lancet Infect Dis 10 2010 43 50
7. C. Lubbert, S. Faucheux, D. Becker-Rux, S. Laudi, A. Dürrbeck, T. Busch, and et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience Int J Antimicrob Agents 42 2013 565 570
8. NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India Antimicrob Agents Chemother 53 2009 5046 5054
9. M.E. Falagas, P. Lourida, P. Poulikakos, P.I. Rafailidis, and G.S. Tansarli Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence Antimicrob Agents Chemother 58 2014 654 663
10. A.P. Zavascki, J.B. Bulitta, and C.B. Landersdorfer Combination therapy for carbapenem-resistant Gram-negative bacteria Expert Rev Anti Infect Ther 11 2013 1333 1353
11. Y. Hu, L. Li, W. Li, H. Xu, P. He, X. Yan, and et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies Int J Antimicrob Agents 42 2013 492 496
12. R.V. Dudhani, J.D. Turnidge, K. Coulthard, R.W. Milne, C.R. Rayner, J. Li, and et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models Antimicrob Agents Chemother 54 2010 1117 1124
13. N. Roussos, D.E. Karageorgopoulos, G. Samonis, and M.E. Falagas Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections Int J Antimicrob Agents 34 2009 506 515
14. Clinical and Laboratory Standards and Institute Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement Document M100-S22 2012 CLSI Wayne, PA
15. P.J. Bergen, J. Li, R.L. Nation, J.D. Turnidge, K. Coulthard, and R.W. Milne Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model J Antimicrob Chemother 61 2008 636 642
16. A.P. MacGowan, C.A. Rogers, H.A. Holt, and K.E. Bwker Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model Antimicrob Agents Chemother 47 2003 1088 1095
17. A.P. MacGowan, K.E. Bowker, and A.R. Noel Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection Antimicrob Agents Chemother 52 2008 1401 1406
18. M. Albur, A. Noel, K. Bowker, and A. MacGowan Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae Antimicrob Agents Chemother 56 2012 3441 3443
19. S.Y. Cho, C.I. Kang, D.R. Chung, K.R. Peck, J.H. Song, and J.H. Jang Breakthrough bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline Antimicrob Agents Chemother 56 2012 4994 4995
20. A. Apisarnthanarak, and L.M. Mundy Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin Int J Antimicrob Agents 39 2012 271 272
21. W. Santimaleeworagun, P. Wongpoowarak, P. Chayakul, S. Pattharachayakul, P. Tansakul, and K.W. Garey In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases Southeast Asian J Trop Med Public Health 42 2011 890 900
22. T. Tängdén, R.A. Hickman, P. Forsberg, P. Lagerbäck, C.G. Giske, and O. Cars Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments Antimicrob Agents Chemother 58 2014 1757 1762
23. S. Corvec, U. Furustrand Tafin, B. Betrisey, O. Borens, and A. Trampuz Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model Antimicrob Agents Chemother 57 2013 1421 1427
24. E. Evren, O.K. Azap, Ş. Çolakoʇlu, and H. Arslan In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains Diagn Microbiol Infect Dis 76 2013 335 338
25. R.L. Nation, J. Li, O. Cars, W. Couet, M.N. Dudley, K.S. Kaye, and et al. Consistent global approach on reporting of colistin doses to promote safe and effective use Clin Infect Dis 58 2014 139 141
26. E. Durante-Mangoni, G. Signoriello, R. Andini, A. Mattei, M. De Cristoforo, P. Murino, and et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial Clin Infect Dis 57 2013 349 358